InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $1.920 -0.37 (-16.16%)+
Announcement
Release
31 Jul 2026 12:08PM
Price at Release
$2.290
Full Release
download
Summary
Clarity Pharmaceuticals Ltd reported a cash balance of $178.3 million as of 30 June 2026, with net operating cash outflows of $19.3 million for the quarter, reflecting their continued investment in clinical trials such as AMPLIFY, CLARIFY, and SECuRE. The company also benefited from a $9.7 million Research and Development Tax Incentive refund. During this period, Clarity's total spending reached $31.2 million, inclusive of clinical trial prepayments, aligning with their strategic financial plans. The report also highlights that payments to related parties were $727,199, which covered director fees and salaries. Clarity maintains a significant portion of its cash reserves in US dollars to match its anticipated spending in the US, ensuring currency exchange fluctuations are mitigated.
Key Points
  • Clarity Pharmaceuticals Ltd ended the quarter with a cash balance of $178.3 million.
  • Net operating cash outflows for the June quarter were $19.3 million.
  • The company received a $9.7 million Research and Development Tax Incentive refund.
  • Quarterly spend was $31.2 million, which included clinical trial prepayments.
  • Funds are being used for the AMPLIFY and CLARIFY Phase III clinical trials and theranostic Phase I/IIa SECuRE study.
  • Payments to related parties, including director fees and salaries, totaled $727,199.
  • The company holds over 60% of its cash reserves in US dollars to support planned US expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.